Drugs Made In America Acquisition II Corp. (DMIIU) Common Equity (2024 - 2025)
Drugs Made In America Acquisition (DMIIU) posted quarterly Common Equity of -$17.8 million for Q4 2025, down 15128.73% year-over-year from N/an in Q4 2024, and down 2.86% quarter-over-quarter from -$17.3 million in Q3 2025.
Drugs Made In America Acquisition II Corp. (DMIIU) Common Equity (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMIIU) has reported Common Equity for 2 consecutive years, with -$17.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 15128.73% year-over-year to -$17.8 million; the TTM figure through Dec 2025 stood at -$17.8 million (down 15128.73% YoY), while the FY2025 annual figure was -$17.8 million, down 15128.73% from the prior year.
- Common Equity fell to -$17.8 million in Q4 2025 per DMIIU's latest filing, from -$17.3 million in the prior quarter.
- Across five years, Common Equity topped out at -$116719.0 in Q4 2024 and bottomed at -$17.8 million in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.77 Mn |
| Sep 30, 2025 | -17.28 Mn |
| Dec 31, 2024 | -116,719.00 |